Elutia(ELUT)

View 1 open job Website LinkedIn Careers Page

Focus: Elutia is a public biotechnology company specializing in drug-eluting biomatrix technology for cardiovascular, oncology, and other therapeutic areas. The company operates at modest scale with $14M in FY2025 revenue and focuses on implantable and regenerative medical products.

Cardiovascular Oncology Unknown

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Elutia?

AI assessment

Elutia offers niche biotech exposure with public company benefits, but financial deterioration and minimal hiring activity signal material execution risk.

Why Work Here

Public company status provides liquidity and potential equity upside in a specialized biotech niche
Diversified pipeline across cardiovascular, orthopedic, and oncology indications offers exposure to multiple therapeutic areas

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

1 open

Revenue

$14M

Key Products

CanGaroo Envelope

Cardiac Disease / Arrhythmias

Growth

Lead cardiac implant envelope product with multiple clinical trial programs underway.

CorMatrix ECM

Cardiovascular Repair (Carotid, Vascular, Pericardial)

Help build intelligence for Elutia

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

CanGaroo

Heart Diseases

N/A

Clinical Trials (1)

NCT04299282CIED Implantation in Low BMI Patients

N/A

CIED envelope

Cardiac Disease

N/A

Clinical Trials (1)

NCT04645173Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation

N/A

CanGaroo Envelope

Cardiac Disease

N/A

Clinical Trials (1)

NCT04351269Retrospective Experience Of CIED Implantation

N/A

ViBone

Spondylosis

N/A

Clinical Trials (1)

NCT03425682ViBone in Cervical and Lumbar Spine Fusion

N/A

CorMatrix ECM for Carotid Repair

Carotid Stenosis

N/A

Clinical Trials (1)

NCT01569594CorMatrix ECM for Carotid Repair Following Endarterectomy Registry

N/A

EluPro Antibiotic-Eluting BioEnvelope

Cardiac Arrhythmias

N/A

Clinical Trials (1)

NCT06854081EluPro Antibiotic-Eluting BioEnvelope Registry

N/A

CorMatrix ECM for Vascular Repair

Peripheral Vascular Disease

N/A

Clinical Trials (1)

NCT02418156A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction

N/A

ViBone®

Spondylolisthesis

N/A

Clinical Trials (1)

NCT03896347A Study Evaluating 3-Level OLIF Spine Fusion

N/A

CorMatrix CanGaroo ECM Envelope

Coronary Disease

N/A

Clinical Trials (1)

NCT02418143A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope

N/A

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

Coronary Disease

N/A

Clinical Trials (1)

NCT02073331Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

N/A

CanGaroo Envelope

Arrhythmias, Cardiac

N/A

Clinical Trials (1)

NCT04846127CanGaroo® Registry Study

N/A

CorMatrix ECM for Pericardial Closure

Atrial Fibrillation New Onset

N/A

Clinical Trials (1)

NCT01247974Evaluation Of New Onset Postoperative Atrial Fibrillation

N/A

SimpliDerm HADM

Breast Cancer

N/A

Clinical Trials (1)

NCT04060134A Retrospective Breast Reconstruction Study

N/A

A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

Cardiovascular Disease

N/A

Clinical Trials (1)

NCT02530970A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

N/A

Interview Prep Quick Facts

Portfolio: 14 clinical trials

Top TAs: Cardiovascular, Oncology

SEC Filings: 2 available

Open Roles: 1 active job

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

6 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$14M42%

R&D Spend

$3M(21%)32%

Net Income

-$54M

Elutia(ELUT)

Should You Work at Elutia?

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Open Jobs (1)

Vice President, Operations

Financials (FY2025)